FERRING-INTERNATIONAL
9.1.2017 14:02:20 CET | Business Wire | Press release
Ferring Pharmaceuticals is partnering with Intralytix, Inc to develop and commercialise bacteriophage-based treatments for conditions associated with the presence of pathogenic bacteria or dysbiosis of the microbiome.
The human body is host to trillions of microbes, bacteria, virus and fungi. This vast and complex microbial community is known as the microbiota. The collective name for all of the genes in the microbiota is the microbiome.
Bacteriophages are a normal part of the microbiota. These virus-like organisms have evolved naturally to target and destroy specific bacteria. They have significant potential compared to antibiotics to treat bacterial infections without affecting beneficial bacteria, such as the normal gut flora, to fine-tune the human microbiome and to address the growing issue of antibiotic resistance.
“Rapidly evolving science is uncovering the central role that the microbiome plays in human health and disease,” said Per Falk, Executive Vice President and Chief Scientific Officer, Ferring Pharmaceuticals. “Ferring is committed to advancing microbiome research in order to develop innovative new ways to diagnose, treat and prevent disease, and to address urgent unmet needs.”
Bacterial resistance to antibiotics is an increasingly serious threat to global public health1 and a key focus of the collaboration will be on developing treatments for multi-drug resistant bacteria.
"Phage-based anti-bacterial treatments are rapidly emerging as a safe, effective and natural way to help maintain healthy microbiota,” said Alexander Sulakvelidze, Vice President for Research and Development and Chief Scientific Officer of Intralytix. “We are delighted to be expanding our collaboration with Ferring. Together, we can enhance product development, and bring benefits to patients more quickly.”
Ferring announced an initial collaboration with Intralytix on a bacteriophage-based therapy for inflammatory bowel disease (IBD) in July 2015. By broadening the collaboration, Ferring and Intralytix will now jointly investigate bacteriophage-based drugs to regulate the microbiome of the female reproductive tract, oral cavity, and skin, in addition to the gut.
ENDS
About the Microbiota
The human body is host to trillions of microbes, bacteria, virus and fungi. This vast and complex microbial community is known as the microbiota. The microbiota can be considered a “new organ” which actually constitutes 2 kg of the body. An estimated 80 % of its components have not yet been cultivated.
About the Microbiome
Each of the different microorganisms in the microbiota has its own unique set of genes. The collective name for all of the genes in the microbiota is the microbiome. Rapidly evolving science has uncovered a central role of the microbiome in human health and disease.
About Bacteriophages
Bacteriophage literally means ‘bacteria-eater’, taken from the Greek ‘phagein’ meaning "to eat". Bacteriophages are the most abundant microorganisms on earth and have evolved naturally to target and destroy specific bacteria. They are currently being investigated as a possible therapy against multi-drug-resistant strains of many bacteria.
About Ferring Pharmaceuticals
Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit www.ferring.com .
About Intralytix, Inc.
Intralytix, Inc. is a privately-held company headquartered in Baltimore, Maryland. The company is the world’s leader in bacteriophage technology, and was the first company in the world to receive FDA-approval for a phage-based product for food safety applications. Intralytix currently has the largest in the world portfolio of phage-based products on commercial markets. The company holds several bacteriophage technology-related patents, including two U.S. patents (and additional patents pending) on the use of bacteriophages for fine tuning human or animal microbiome by using phage to reduce or eliminate bacterial colonization (US 7,459,272 B2 and US 8,003,323 B2). To learn more about Intralytix, Inc. or its products please visit www.intralytix.com
1 WHO Antimicrobial Fact sheet 2016 : http://www.who.int/mediacentre/factsheets/fs194/en/
View source version on businesswire.com: http://www.businesswire.com/news/home/20170109005710/en/
Contact:
Ferring Pharmaceuticals
Lindsey Rodger
Tel. +41 58 451
40 23
lindsey.rodger@ferring.com
or
Intralytix
Alexander
Sulakvelidze
Tel. +1 410 625 2533
asulakvelidze@intralytix.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dreamstime Adds Ten More Language Versions, Reaching 23 in Total29.1.2026 13:00:00 CET | Press release
Dreamstime, the world’s largest stock photography community, announced today the addition of new language versions—Czech, Japanese, Korean, Hindi, Turkish, Indonesian, Danish, and Norwegian—to expand its global reach and provide a more comprehensive digital experience worldwide. Hebrew and Arabic will be launched next. Key Takeaways: Dreamstime expands into 23 languages, increasing global reach and accessibility. AI-powered translation improves search relevance, onboarding, and cultural discovery. With billions of new pages and coverage in almost every country worldwide in native, official, or very popular languages, this is Dreamstime’s most prolific launch in its 25-year history. The platform already operates in 13 languages: English, French, Polish, Italian, Spanish, Portuguese, Dutch, Russian, Greek, Chinese, Swedish, German, and Romanian. With a stock photography collection of over 350 million files and millions of new items added monthly, Dreamstime manages a constantly growing d
NIQ Launches Breakthrough Framework That Exposes Billions Lost to the Say–Do Gap29.1.2026 13:00:00 CET | Press release
The new global framework quantifies the disconnect between consumer intent and real‑world buying behavior, unlocking powerful paths to reclaim volume and fuel growth NielsenIQ (NYSE: NIQ) today announced the launch of its Say–Do Gap Measurement Framework, an innovative behavioral metric set to transform how brands and retailers understand modern consumers and navigate a pressing challenge: consumers who say one thing but buy another. With economic uncertainty, shifting priorities, and increasingly value‑driven decision-making changing consumer habits, this growing disconnect has cost the industry more than 13 billion unit sales over the past five years—losses many companies can no longer afford to overlook. By unifying deep attitudinal insights with verified purchase data across 25+ global markets, the Say–Do Framework bridges this gap and exposes where brands are losing momentum, where unmet demand is hiding, and where opportunity is silently compounding. Brands and retailers can now
IDDI Reveals New Brand & Celebrates 35 Years of Clinical Data Science Excellence29.1.2026 13:00:00 CET | Press release
IDDI, a global clinical data science partner with more than 35 years of proven quality, today announced the launch of its refreshed brand. The new brand highlights the company’s continued focus on patients and commitment to innovation while honoring its legacy of scientific rigor. The launch coincides with IDDI’s 35-year anniversary and will debut publicly at the SCOPE Summit on Feb. 2, 2026. Biomedical research is shifting toward more complex trials and advanced analytics. But, as one survey revealed, only 46% of life science leaders are fully confident their organization’s data are consistently available and accurate. IDDI’s new brand reinforces that their services are the solution, explaining how they deliver high-quality data and mitigate risk from design to registration and beyond. “Reaching 35 years is an important milestone, not only because of our longevity, but because of the impact we’ve had,” said Marc Buyse, ScD, founder and CEO of IDDI. “Our new brand reflects the heart of
Media Release: Jannik Sinner and Allianz Announce Multi-Year Global Partnership29.1.2026 11:04:00 CET | Press release
Jannik Sinner becomes Global Brand Ambassador of the world’s most valuable insurance brand.The partnership broadens Allianz’s established sports collaborations; the large tennis fan base worldwide will drive emotional engagement with Allianz.“We’re here to serve” captures the spirit of both partners; joint projects with The Jannik Sinner Foundation aim to support children’s future. Tennis star Jannik Sinner and Allianz Group announced a multi-year global partnership today, with the leading insurer and asset manager becoming an official partner of the four-time Grand Slam champion. Boasting approximately 300 million fans worldwide and a billion-strong ATP global fan base, tennis is the second-most popular sport behind football across Allianz key markets. A cornerstone of the collaboration is empowering children and youth through education and sport, providing them with enhanced opportunities for growth, health, and future success. This partnership also expands Allianz's involvement in s
How Aker Security Builds Control Rooms for Real-Time Decision-Making29.1.2026 10:00:00 CET | Press release
In a new case, Aker Security demonstrates how a control room built on Cyviz’ technology platform functions as the operational nerve center for decision-making, collaboration, and preparedness. In today’s security landscape, the challenge lies in aggregating, visualizing, and using large volumes of data effectively in situations where time, precision, and coordination are critical. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260129578139/en/ GSOC Aker Security oversees security and preparedness for large parts of the Group, covering several thousand employees. Its services include travel security, global event and incident monitoring, crisis management, and security advisory services. "We approached Cyviz because we needed a solution that could bring everything together on a single platform, while at the same time supporting the way we actually work operationally," says Tonje Evensen Bråthen, Head of the Global Security Op
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom